Why it matters in the plan
Biopharmaceuticals and biomanufacturing are named among the strategic emerging and highlighted new industries. The plan also points toward innovative drugs, cell and gene therapies, advanced diagnostics, and intelligent medical equipment.
This is a broad life-science and health-technology cluster. Its social dimension is visible in the link between innovation capacity, medical services, public health, and the technologies that can support diagnosis and treatment.
What the plan calls for
- Develop biomanufacturing and biopharmaceutical capabilities.
- Advance innovative drugs, cell and gene therapies, and advanced diagnostics.
- Improve high-end medical devices and intelligent surgical equipment.